Trendlines gets grant for urinary incontinence device

Israeli innovator, along with SIngapore hospital, is developing self-administered product to act as ‘shock absorber’

Shoshanna Solomon is The Times of Israel's Startups and Business reporter

Trendlines' SUI device for home use (Courtesy)
Trendlines' SUI device for home use (Courtesy)

Trendlines Labs is to receive a grant from the Singapore Israel Industrial Research and Development Foundation for the development and clinical trial of its stress urinary incontinence (SUI) product, which is being developed in partnership with the Singapore General Hospital.

The 50 women in the trial, expected to start mid-2017 at the hospital, will provide feedback on the product. The foundation will provide up to 50 percent of the $400,000 the partners need to fund the final product development and clinical trial.

Trendlines Labs, the innovation arm of The Trendlines Group Ltd., the Israeli venture fund and tech accelerator firm, has developed a nonsurgical, non-pharmaceutical solution to mitigate SUI, a form of incontinence that affects approximately 15 million women in the US alone, according to the Women’s Health Foundation. SUI is caused by weak sphincter muscles or weak pelvic floors, and can occur when there is abdominal stress on the pelvic organs — the bladder, vagina, uterus, or rectum.

The device will provide women who suffer from the condition with a simple-to-use, self-administered home treatment. The over-the-counter device is based on the principles of physics, and introduces a small amount of gas into the bladder. The gas acts as a shock absorber to reduce the pressure (stress) applied to the bladder, thereby eliminating or greatly decreasing the involuntary loss of urine. Woman attach a thin, sterile, biocompatible, single-use applicator to the device and then manually insert the applicator into the urethra. By pressing a button, a small, pre-defined amount of gas is released into the bladder to generate immediate relief.

In the framework of the collaboration agreement, Trendlines Labs and Singapore General Hospital will work together using the technology to implement the clinical trial at the hospital, where the management and collection of clinical data will take place. Upon commercialization of the device, both bodies in the agreement will get royalties from the development.

The Trendlines Group focuses on inventing technologies and products to meet critical unmet market needs.

Singapore General Hospital is the first and largest hospital in Singapore. It is wholly owned by the government of Singapore and is the flagship hospital of the country’s public healthcare system.

read more:
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed